Literature DB >> 16418065

Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride.

N Tani1, M Yabuki, S Komuro, H Kanamaru.   

Abstract

The in vitro metabolism of amrubicin by rat and human liver microsomes and cytosol was examined. The main metabolic routes in both species were reductive deglycosylation and carbonyl group reduction in the side-chain. In vitro metabolism of amrubicinol by rat and human liver microsomes and cytosol was also examined and the main metabolic route of this active metabolite was reductive deglycosylation. Metabolism of amrubicin in human liver microsomes was inhibited by TlCl(3) and that in human liver cytosol was inhibited by dicumarol and quercetin. Generation of amrubicinol was inhibited only by quercetin. The results indicate that metabolism of amrubicin is mediated by NADPH-cytochrome P450 reductase, NADPH:quinone oxidoreductase and carbonyl reductase. In addition, generation of amrubicinol is mediated by carbonyl reductase. Metabolism of amrubicinol in human liver microsomes was inhibited by TlCl(3) and that in human liver cytosol was inhibited by dicumarol. The results indicate that metabolism of amrubicinol is mediated by NADPH-cytochrome P450 reductase and NADPH:quinone oxidoreductase. To investigate the influence of cisplatin on the metabolism of amrubicin and amrubicinol, human liver microsomes and cytosol were pre-incubated with cisplatin. This did not change the rates of amrubicin and amrubicinol metabolism in either human liver microsomes or cytosol.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16418065     DOI: 10.1080/00498250500342746

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  11 in total

1.  Occurrence of Hematological Malignancy in Long-term Survivors With Advanced Thymic Cancer.

Authors:  Kyoichi Kaira; Ichiro Naruse; Shu Shinomiya; Hiroshi Kagamu
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes.

Authors:  Kaori Matsumoto; Tetsuya Hasegawa; Junichi Koyanagi; Tamiko Takahashi; Masayuki Akimoto; Kenji Sugibayashi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-06       Impact factor: 2.441

3.  Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study.

Authors:  Koji Takeda; Nobuhide Takifuji; Shunichi Negoro; Kiyoyuki Furuse; Shinichiro Nakamura; Yoshiki Takada; Takanobu Hoso; Shinichi Hayasaka; Takashi Nakano; Jun Araki; Hiroshi Senba; Fumiyuki Iwami; Yasufumi Yamaji; Masahiro Fukuoka; Harumichi Ikegami
Journal:  Invest New Drugs       Date:  2007-03-10       Impact factor: 3.850

4.  Tandem laser-induced fluorescence and mass spectrometry detection for high-performance liquid chromatography analysis of the in vitro metabolism of doxorubicin.

Authors:  Joseph B Katzenmeyer; Christopher V Eddy; Edgar A Arriaga
Journal:  Anal Chem       Date:  2010-10-01       Impact factor: 6.986

5.  Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer.

Authors:  Kyoichi Kaira; Noriaki Sunaga; Hisao Imai; Yosuke Kamide; Yasuhiko Koga; Akihiro Ono; Tomohito Kuwako; Tomomi Masuda; Takeshi Hisada; Tamotsu Ishizuka; Masanobu Yamada
Journal:  Int J Clin Oncol       Date:  2015-08-13       Impact factor: 3.402

6.  Quinone-enhanced reduction of nitric oxide by xanthine/xanthine oxidase.

Authors:  Pedro Sanchez-Cruz; Antonio E Alegría
Journal:  Chem Res Toxicol       Date:  2009-05       Impact factor: 3.739

7.  C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin.

Authors:  Misato Nagata; Tatsuo Kimura; Tomohiro Suzumura; Yukimi Kira; Toshiyuki Nakai; Kanako Umekawa; Hidenori Tanaka; Kuniomi Matsuura; Shigeki Mitsuoka; Naruo Yoshimura; Takako Oka; Shinzoh Kudoh; Kazuto Hirata
Journal:  Clin Med Insights Oncol       Date:  2013-02-13

Review 8.  Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer.

Authors:  Qian Ding; Jinbiao Zhan
Journal:  Drug Des Devel Ther       Date:  2013-08-01       Impact factor: 4.162

9.  A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.

Authors:  Hisao Imai; Tomohide Sugiyama; Tomohiro Tamura; Hiroyuki Minemura; Kyoichi Kaira; Kenya Kanazawa; Hiroshi Yokouchi; Takashi Kasai; Takayuki Kaburagi; Koichi Minato
Journal:  Cancer Chemother Pharmacol       Date:  2017-07-31       Impact factor: 3.333

10.  Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin.

Authors:  Reiko Sakurai; Kyoichi Kaira; Yosuke Miura; Noriaki Sunaga; Ryusei Saito; Tetsunari Oyama; Takeshi Hisada; Masanobu Yamada
Journal:  Thorac Cancer       Date:  2020-01-03       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.